tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Enliven Therapeutics Inc

ELVN
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
45.960USD
-0.550-1.18%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย 09/30, 12:28๏ผˆET๏ผ‰
3.21B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

ELVN ์žฌ๋ฌด ๋ฐ์ดํ„ฐ

์Šค๋งˆํŠธํ•œ ํˆฌ์ž์ž๋ฅผ ์œ„ํ•ด ์„ค๊ณ„๋œ ์˜ฌ์ธ์› ๋ฐ์ดํ„ฐ ๋Œ€์‹œ๋ณด๋“œ๋ฅผ ํ†ตํ•ด Enliven Therapeutics Inc์˜ ์žฌ๋ฌด ๋ฐ์ดํ„ฐ๋ฅผ ํ™•์ธํ•˜์„ธ์š”. ๋ณต์žกํ•œ ์žฌ๋ฌด์ œํ‘œ๋ฅผ ์‚ฌ์šฉ์ž ์ •์˜ ๊ฐ€๋Šฅํ•œ ๋ทฐ๋กœ ๊ตฌ์„ฑํ•˜์—ฌ ์žฌ๋ฌด ๋ถ„์„์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ตœ์‹  ์—ฐ๊ฐ„ ์žฌ๋ฌด ๋ณด๊ณ ์„œ์— ์ ‘๊ทผํ•˜๊ฑฐ๋‚˜, ์†์ต๊ณ„์‚ฐ์„œ, ์žฌ๋ฌด์ƒํƒœํ‘œ, ํ˜„๊ธˆ ํ๋ฆ„ํ‘œ๋ฅผ ์‚ฌ์šฉํ•˜์—ฌ ๋ถ„๊ธฐ๋ณ„ ์„ฑ๊ณผ๋ฅผ ๋ถ„์„ํ•˜์„ธ์š”. ์‹ค์‹œ๊ฐ„ ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ์†๋์—์„œ ํ™•์ธํ•  ์ˆ˜ ์žˆ์–ด ํšŒ์‚ฌ์˜ ์‹œ์žฅ ๊ฑด์ „์„ฑ์„ ์‹œ๊ฐ„์— ๋”ฐ๋ผ ๊ทธ ์–ด๋А ๋•Œ๋ณด๋‹ค ์‰ฝ๊ฒŒ ๋ชจ๋‹ˆํ„ฐ๋งํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ•ต์‹ฌ ์žฌ๋ฌด ๋น„์œจ

์‹œ๊ฐ€์ด์•ก
3.21B
๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.00
P/E TTM
-28.09
์ฃผ๋‹น์ˆœ์ด์ต
-1.64
์ˆ˜์ต
--
์ˆœ์ด์ต
-89.02M
ROE
-26.64%
ROA
-25.74%

Enliven Therapeutics Inc ์‹ค์  ๋ฐœํ‘œ์ผ๎˜

์ตœ์‹  ์ถœ์‹œ
Aug 5, 2026
EPS / ์˜ˆ์ƒ
-0.49/-0.40
์ˆ˜์ต / ์˜ˆ์ƒ
--/0.00

์žฌ๋ฌด์ œํ‘œ ์š”์•ฝ

๋ถ„๊ธฐ๋ณ„๎˜ฎ
๋ถ„๊ธฐ๋ณ„+์—ฐ๊ฐ„
๋ถ„๊ธฐ๋ณ„
์—ฐ๊ฐ„
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
์žฌ๋ฌด ์ง€ํ‘œ
EPS
-0.96%-0.49
34.03%-0.38
-2.51%-0.48
32.36%-0.32
-17.17%-0.49
-5.46%-0.57
1.18%-0.46
5.22%-0.48
-1.66%-0.41
32.00%-0.54
-109.60%-0.47
---0.51
---0.41
---0.80
--4.90
----
----
----
----
----
์ˆœ์ด์ต
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
๋ถ€์ฑ„๋น„์œจ
----
----
----
----
----
----
----
----
----
----
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
----
----
----
----
----
์˜์—… ์ด์ต
-30.17%-37.21M
12.21%-27.82M
-27.47%-34.28M
7.29%-25.10M
-16.18%-28.58M
-21.96%-31.69M
-18.33%-26.90M
-11.63%-27.07M
-22.20%-24.60M
-58.28%-25.99M
-597.85%-22.73M
-401.93%-24.25M
-74.76%-20.13M
-11.98%-16.42M
77.28%-3.26M
64.63%-4.83M
12.51%-11.52M
-42.62%-14.66M
-24.10%-14.33M
-9.32%-13.66M
์ˆœ์ด์ต
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
-9.85%-13.65M
์œ ๋™์ž์‚ฐ
83.07%907.34M
57.36%463.14M
49.27%474.88M
62.52%482.68M
55.79%495.62M
-12.72%294.32M
19.53%318.13M
10.57%297.00M
12.34%318.13M
13.15%337.20M
196.92%266.15M
354.46%268.61M
340.70%283.18M
279.49%298.00M
-3.30%89.64M
-44.24%59.10M
-9.95%64.26M
-2.28%78.53M
2.53%92.70M
6.30%106.00M
์œ ๋™ ๋ถ€์ฑ„ ์ด๊ณ„
-6.90%14.16M
-17.79%11.49M
4.10%16.57M
-13.96%14.65M
-31.19%15.21M
-44.18%13.97M
-38.54%15.91M
40.96%17.03M
141.66%22.11M
128.76%25.03M
1314.97%25.89M
564.41%12.08M
177.01%9.15M
51.49%10.94M
-74.62%1.83M
-74.71%1.82M
-52.65%3.30M
31.26%7.22M
15.42%7.21M
35.37%7.19M
์ด ์ž์‚ฐ
80.64%910.22M
53.63%464.85M
46.17%476.17M
60.72%490.88M
54.07%503.89M
-11.73%302.57M
19.82%325.76M
11.45%305.43M
13.36%327.04M
13.18%342.78M
195.64%271.87M
363.66%274.04M
346.14%288.50M
271.15%302.87M
-1.80%91.96M
-44.78%59.10M
-10.77%64.67M
-0.10%81.60M
3.09%93.65M
6.84%107.03M
๋ถ€์ฑ„ ์ด๊ณ„
-2.21%15.07M
-19.53%11.49M
4.10%16.57M
-13.36%14.75M
-30.28%15.41M
-43.05%14.27M
-38.70%15.91M
38.51%17.03M
132.58%22.11M
118.91%25.07M
1318.63%25.96M
576.18%12.29M
187.92%9.51M
24.59%11.45M
-75.97%1.83M
-76.25%1.82M
-55.98%3.30M
50.83%9.19M
18.87%7.62M
39.75%7.65M
์ž๋ณธ ์ด๊ณ„
83.25%895.15M
57.26%453.37M
48.33%459.60M
65.09%476.12M
60.19%488.47M
-9.26%288.30M
26.00%309.85M
10.18%288.40M
9.30%304.93M
9.02%317.71M
172.84%245.91M
356.91%261.75M
354.65%278.99M
302.44%291.42M
4.76%90.13M
-42.35%57.29M
-5.55%61.36M
-4.21%72.41M
1.89%86.03M
4.94%99.37M
์ˆœ์˜์—…์ด์ต
-8.64%-18.53M
20.04%-19.29M
7.93%-15.84M
-8.91%-13.28M
16.53%-17.06M
-3.28%-24.13M
-37.82%-17.20M
23.29%-12.19M
-69.60%-20.43M
-12.08%-23.36M
-563.94%-12.48M
-278.34%-15.89M
2.26%-12.05M
-21.47%-20.84M
84.94%-1.88M
61.46%-4.20M
-18.93%-12.33M
-31.80%-17.16M
-50.99%-12.48M
-5.36%-10.90M
์ˆœํˆฌ์ž
-140.52%-441.57M
2880.10%42.53M
1602.75%12.38M
-127.37%-4.06M
-445.34%-183.59M
107.98%1.43M
-98.12%727.00K
141.71%14.83M
77.78%-33.66M
-57593.55%-17.89M
-7.49%38.69M
-254.00%-35.55M
-2514.24%-151.52M
-100.58%-31.00K
388.59%41.82M
361.37%23.08M
85.24%6.28M
-70.85%5.33M
-168.32%-14.49M
14.10%-8.83M
์ˆœ์žฌ๋ฌดํ™œ๋™
112.21%463.42M
4196.15%10.05M
-98.44%623.00K
-132.95%-368.00K
11991.81%218.38M
-99.74%234.00K
44313.33%39.97M
362.82%1.12M
164.04%1.81M
-61.98%90.27M
107.30%90.00K
---425.00K
---2.82M
--237.44M
-12230.00%-1.23M
-100.00%0.00
-100.00%0.00
-100.00%0.00
-101.68%-10.00K
34708.15%46.99M

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Enliven Therapeutics Inc์˜ ์œ ๋™์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์œ ๋™์ž์‚ฐ์€ 474.88M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 49.27์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Enliven Therapeutics Inc์˜ ์ด์ž์‚ฐ์€ 476.17M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 46.17์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Enliven Therapeutics Inc์˜ ์ด๋ถ€์ฑ„๋Š” 16.57M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 4.10์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ด์ž๋ณธ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Enliven Therapeutics Inc์˜ ์ด์ž๋ณธ์€ 459.60M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 48.33์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Enliven Therapeutics Inc์˜ ์ˆœ์˜์—…์†Œ๋“์€ -119.66M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -14.45์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Enliven Therapeutics Inc์˜ ์ˆœํˆฌ์ž๋Š” -173.84M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -382.93์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, Enliven Therapeutics Inc์˜ ์ˆœ์ž๊ธˆ์กฐ๋‹ฌ์€ 218.87M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 64.36์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ฃผ๋‹น์ˆœ์ด์ต(EPS)์€ -1.83์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 3.24์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ˆœ์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ˆœ์ด์ต์€ -103.69M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -16.48์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ž๊ธฐ์ž๋ณธ์ด์ต๋ฅ (ROE)์€ -26.95์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 15.87์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์ด์ž์‚ฐ์ด์ต๋ฅ (ROA)์€ -25.86์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” 13.20์ž…๋‹ˆ๋‹ค.

Enliven Therapeutics Inc์˜ ์˜์—…์ด์ต์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Enliven Therapeutics Inc์˜ FY2025 ์‹ค์  ๋ณด๊ณ ์„œ์— ๋”ฐ๋ฅด๋ฉด, ์˜์—…์ด์ต์€ -119.66M์ด๋ฉฐ, ์ „๋…„ ๋Œ€๋น„ ๋ณ€๋™์น˜๋Š” -14.45์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ